Welcome to our dedicated page for Small Pharma news (Ticker: DMTTF), a resource for investors and traders seeking the latest updates and insights on Small Pharma stock.
Small Pharma Inc. (DMTTF) is a pharmaceutical company focused on developing novel treatments for mental health disorders. With a strong emphasis on research and innovation, Small Pharma aims to revolutionize the treatment landscape for conditions like depression, PTSD, and anxiety.
The company's cutting-edge pipeline includes proprietary compounds that have shown promising results in preclinical studies. Small Pharma's approach prioritizes patient-centered care and strives to address the unmet needs of individuals suffering from mental health issues.
Small Pharma has established strategic partnerships with leading research institutions and experts in the field of psychiatry, ensuring a comprehensive and rigorous approach to drug development. The company's dedication to scientific excellence and patient well-being sets it apart in the competitive pharmaceutical industry.
Small Pharma reported its financial results for the fiscal year ended February 28, 2022, showing cash on hand of $40.7 million. Operating expenses reached $18.1 million, with $16.2 million used in operating activities. The company is advancing its lead program, SPL026, in a Phase IIa trial for major depressive disorder, with patient dosing completion expected soon. Additionally, it strengthened its patent portfolio with six granted and 74 applications pending. The executive team was enhanced with new appointments to support the pipeline.
Small Pharma Inc. (TSXV: DMT, OTCQB: DMTTF) will present at the Jefferies Healthcare Conference on June 10, 2022, at 11:30 AM ET. The presentation will be led by CEO Peter Rands and Dr. Carol Routledge, Chief Medical and Scientific Officer. Interested parties can register for the live webcast here. Small Pharma focuses on DMT-assisted therapies for mental health, particularly depression, and is advancing its clinical program initiated in February 2021.
Small Pharma Inc. (DMTTF) appointed Alastair Riddell as COO to strengthen its leadership team. The company received two new patents for its psychedelic therapies, bringing its total to six granted patents. The ongoing Phase IIa clinical trial of SPL026 for Major Depressive Disorder is progressing, with improved patient recruitment. Small Pharma has $40.7 million in cash as of February 28, 2022. Upcoming announcements include Phase IIa trial results and new study plans for SPL026 later this year.
Small Pharma will participate in the PSYCH Symposium: London 2022 on May 11, 2022, discussing the future of psychedelic healthcare. Dr. Carol Routledge, the company's Chief Medical and Scientific Officer, will speak on Dynamic Drug Development at The National Gallery in London. Small Pharma focuses on short-acting psychedelic therapies for mental health, with a lead clinical program on DMT initiated in February 2021. The symposium provides a platform for investor meetings and further insights into DMT-assisted psychotherapy for depression.
Small Pharma (DMTTF) announces significant advancements in its DMT-assisted therapy candidates SPL026 and SPL028. Two new clinical trials for SPL026 are set for 2022, focusing on the interaction of DMT with antidepressants, particularly in patients suffering from Major Depressive Disorder. Meanwhile, SPL028 is progressing towards a Phase I trial in H2 2022, following promising preclinical data. SPL028 aims to provide an extended psychedelic experience while maintaining a favorable safety profile similar to SPL026.
Small Pharma Inc. is set to participate in the 34th Annual Roth Conference in Dana Point, CA, from March 13-15, 2022. The events will include a fireside chat featuring CEO Peter Rands and Chief Medical and Scientific Officer, Dr. Carol Routledge, on March 14 from 3:30 PM to 3:55 PM PT. Additionally, Small Pharma will contribute to a panel discussion on psychedelics as mental health treatments. The company focuses on DMT-assisted therapy for depression and is advancing its clinical program alongside Imperial College London.
Small Pharma has announced positive findings from its Phase I trial of SPL026, a psychedelic-assisted therapy for Major Depressive Disorder (MDD). The trial, involving 32 participants, showed strong safety profiles with no serious adverse events and increasing quality in psychedelic experiences correlating with doses between 9mg and 21.5mg. Notably, participant-reported experiences improved dramatically with dosage, reaching scores up to 88 at the highest level. A Phase IIa study is on track for topline results in mid-2022, which could further validate these encouraging outcomes.
Small Pharma Inc. (TSXV: DMT, OTCQB: DMTTF) reported significant advancements in its clinical portfolio, particularly with its lead candidate, SPL026, undergoing a successful Phase I/IIa trial for Major Depressive Disorder. The company anticipates full Phase I data shortly and aims for topline results from Phase IIa in H1 2022. Positive discussions with the FDA indicate a multi-site Phase IIb trial may start in H2 2022. Financially, Small Pharma holds $45.6 million in cash, with operating expenses of $4.6 million for Q3 2021.
Small Pharma Inc. (OTCQB: DMTTF) is participating in two upcoming virtual conferences: the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022, featuring a panel discussion on psychedelics, and the H.C. Wainwright Bioconnect Conference from January 10-13, 2022, with an on-demand fireside chat. Small Pharma focuses on developing DMT-assisted therapies for mental health conditions, particularly depression. The ongoing clinical program aims to provide innovative treatment options for mental health challenges.
Small Pharma announced participation in the H.C. Wainwright 2nd Annual Psychedelics Conference, scheduled for December 6, 2021. A webcast presentation by CEO Peter Rands will be available on demand starting at 7:00 a.m. ET. The company focuses on psychedelic-assisted therapies for mental health, highlighting its DMT-assisted therapy program initiated in February 2021. Small Pharma is leading the first clinical trial globally for DMT in major depressive disorder.
FAQ
What is the market cap of Small Pharma (DMTTF)?
What is Small Pharma Inc. focused on?
What sets Small Pharma apart in the pharmaceutical industry?
What is Small Pharma's pipeline like?
Who does Small Pharma collaborate with?
What conditions does Small Pharma target?
How does Small Pharma prioritize patient well-being?
What results has Small Pharma achieved in preclinical studies?
What is Small Pharma's mission?
Where can I find the latest news about Small Pharma Inc.?
How does Small Pharma contribute to the pharmaceutical industry?
